ClinicalTrialsFinder
RecruitingPhase 1NCT06826313

A Study of Intravenous VRT106 for Locally Advanced or Metastatic Solid Tumors

An Open-labeled Phase I Clinical Trial Evaluating the Safety, Tolerability, Biodistribution Characteristics, Biological EEffects, and Initial Efficacy of VRT106 for Injection in the Treatment of Locally Advanced/Metastatic Solid Tumors by Intravenous Administration

Sponsor

Guangzhou Virotech Pharmaceutical Co., Ltd.

Enrollment

12 participants

Start Date

Mar 19, 2025

Study Type

INTERVENTIONAL

Conditions

Solid Tumors

Summary

A Phase I Study of the Safety and Tolerability of VRT106 Administered Intravenously for Treatment of Patients With Locally Advanced or MetastaticSolid Tumors

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called VRT106 for people with solid tumors. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALVRT106

Intravenous drip administration

Locations(1)

The Third Affiliated Hospital of Sun Yat-sen University

Guangzhou, Guangdong, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06826313

Related Trials

A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma

NCT07522073215 locations

A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies

NCT0719591622 locations

A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors

NCT0718168114 locations

A Study of GEN1106 in Participants With Solid Tumors

NCT074161238 locations

Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

NCT03486873780 locations